Lazard Asset Management LLC Takes Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Lazard Asset Management LLC acquired a new position in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 73,189 shares of the company's stock, valued at approximately $1,225,000. Lazard Asset Management LLC owned approximately 0.06% of Centessa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of CNTA. Barclays PLC raised its position in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after acquiring an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in Centessa Pharmaceuticals in the fourth quarter worth $162,000. China Universal Asset Management Co. Ltd. raised its position in Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after acquiring an additional 5,316 shares in the last quarter. Ameriprise Financial Inc. purchased a new position in Centessa Pharmaceuticals in the fourth quarter worth $320,000. Finally, XTX Topco Ltd raised its position in Centessa Pharmaceuticals by 122.9% in the fourth quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after acquiring an additional 12,506 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company's stock.

Centessa Pharmaceuticals Trading Up 2.0%

NASDAQ:CNTA traded up $0.25 on Friday, reaching $12.87. The stock had a trading volume of 726,678 shares, compared to its average volume of 647,220. Centessa Pharmaceuticals plc has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -8.41 and a beta of 1.53. The firm's fifty day moving average is $13.06 and its two-hundred day moving average is $15.47. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.15. Equities analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the sale, the chief executive officer now directly owns 276,017 shares of the company's stock, valued at $4,606,723.73. This trade represents a 16.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arjun Goyal purchased 44,939 shares of the firm's stock in a transaction on Thursday, May 15th. The shares were purchased at an average cost of $12.24 per share, for a total transaction of $550,053.36. Following the completion of the purchase, the director now directly owns 44,939 shares in the company, valued at $550,053.36. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 165,398 shares of company stock valued at $2,423,242 in the last ninety days. Insiders own 7.09% of the company's stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Chardan Capital assumed coverage on Centessa Pharmaceuticals in a research report on Thursday, May 8th. They issued a "buy" rating and a $30.00 price objective for the company. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 price objective on the stock. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 price objective on the stock. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $27.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.